Parallel imports of medicines spells success for Delfarma

Parallel importation enables the company to buy drugs which are cheaper than in Poland in other EU countries, and - after re-packaging - to sell them on the domestic market. "According to our initial estimations, the drugs were well received in Poland thanks to their comparatively low price," said Tomasz Dzitko, Delfarma's president. Drugs from parallel imports are on average 15-25% cheaper than the ones offered in the traditional way. According to Tomasz Dzitko, the company's main problem is now the reluctance of pharmaceutical concerns, which try to impose limitations on parallel importing. Delfarma's revenues in 2005 will increase to around zł.50 million, as compared to zł.30 million in 2004. The company also plans to increase its revenues to zł.100 million in two years time. (Parkiet, p. 6) A.F.